Muscles in Liver Diseases (UNIVERSE)
Cirrhosis is the 11th leading cause of death in the world. The progression to cirrhosis occurs as a result of chronic hepatic injury, related to excessive alcohol consumption, non-alcoholic steatohepatitis, chronic viral infection. Cirrhosis is accompanied by symptoms that profoundly affect the quality of life of patients.
Sarcopenia, or decrease in muscle capacity through loss of muscle mass, is associated with liver disease. Patients with liver disease and sarcopenia have increased morbidity, and higher pre- and post-liver transplant mortality than patients without sarcopenia. The mechanism responsible for the development of sarcopenia in liver disease remains largely misunderstood, as do the mechanisms by which sarcopenia appears to promote complications of liver disease.
This study, carried out on a prospective cohort of patients with liver disease, aims at understanding the pathophysiological mechanisms involved in sarcopenia and its consequences.
연구 개요
상태
상세 설명
Cirrhosis is the 11th leading cause of death in the world. The progression to cirrhosis occurs as a result of chronic hepatic injury, related to excessive alcohol consumption, non-alcoholic steatohepatitis, and chronic viral infection. Cirrhosis is accompanied by symptoms that profoundly affect the quality of life of patients.
Sarcopenia, or decrease in muscle capacity through loss of muscle mass, is associated with liver disease. Patients with liver disease and sarcopenia have increased morbidity, and higher pre- and post-liver transplant mortality than patients without sarcopenia. The mechanism responsible for the development of sarcopenia in liver disease remains largely misunderstood, as do the mechanisms by which sarcopenia appears to promote complications of liver disease.
This study, carried out on a prospective cohort of patients with stable liver disease, aims at understanding the pathophysiological mechanisms involved in sarcopenia and its consequences.
After checking the inclusion criteria, all eligible patients treated at Beaujon Hospital (Clichy) will be invited to participate in the study. After inclusion, clinical and laboratory features (hepatic assessment) will be collected and the blood samples will be taken.
During the surgery, a muscle biopsy will be performed on the incision area. No follow-up is planned.
연구 유형
등록 (예상)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: pierre Emmanuel Rautou
- 전화번호: 33 140875283
- 이메일: pierre.emmanuel.rautou@aphp.fr
연구 연락처 백업
- 이름: Enis Kostallari
- 전화번호: 33 140875283
- 이메일: enis.kostallari@gmail.com
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patients over the age of 18 having a scheduled abdominal surgery at Beaujon Hospital
- Patient affiliated to a social security scheme
- Informed patient having signed a consent to participate
Exclusion Criteria:
Primary muscle disease (myopathy, dermatopolymyositis, vasculitis with muscle involvement)
- Amyotrophic drugs: long-term corticosteroid therapy
- Immunosuppressive treatments
- Chronic inflammatory disease (example: Crohn's disease)
- Disease known to cause sarcopenia such as -but not limited to- active extrahepatic neoplasia, polycystic hepatorenal disease
- Gastrointestinal haemorrhage in the 15 days prior to inclusion
- Acute alcoholic hepatitis in the month before inclusion
- Infection during treatment
- Pregnant or breastfeeding woman
- Protected populations: people under guardianship or under guardianship
- Patient not affiliated to a social security scheme
- Patient under AME
- Patient not having signed consent
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
다른: patients without liver disease,
taking blood samples and biopsy of muscular wall
|
3 citrated tubes and 3 EDTA tubes
a muscle biopsy will be performed on the incision area
|
|
다른: patient with chronic liver disease without cirrhosis,
taking blood samples and biopsy of muscular wall
|
3 citrated tubes and 3 EDTA tubes
a muscle biopsy will be performed on the incision area
|
|
다른: patients with compensated cirrhosis,
taking blood samples and biopsy of muscular wall
|
3 citrated tubes and 3 EDTA tubes
a muscle biopsy will be performed on the incision area
|
|
다른: patient with severe cirrhosis
taking blood samples and biopsy of muscular wall
|
3 citrated tubes and 3 EDTA tubes
a muscle biopsy will be performed on the incision area
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
describe the muscle changes that occur during liver disease.
기간: 1 month after the of inclusion
|
Assessment of the histology of the muscle removed during abdominal surgery by measuring the diameter of muscle fibers
|
1 month after the of inclusion
|
|
describe the muscle changes that occur during liver disease.
기간: 1 month after the of inclusion
|
Assessment of the histology of the muscle removed during abdominal surgery, by evaluating the vascularity with measurements of CD31 count and αSMA count
|
1 month after the of inclusion
|
|
describe the muscle changes that occur during liver disease.
기간: 1 month after the of inclusion
|
Assessment of the histology of the muscle removed during abdominal surgery by evaluating the muscle stem cells with measurements of Pax7, MyoD and Myogenin
|
1 month after the of inclusion
|
|
describe the muscle changes that occur during liver disease.
기간: 1 month after the of inclusion
|
Assessment of the histology of the muscle removed during abdominal surgery by evaluating gene expression with transcriptomics
|
1 month after the of inclusion
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Identify circulating mediators that could be responsible for sarcopenia: released by the liver and acting on the muscle.
기간: 1 month after the of inclusion
|
Circulating concentration of mediators / cells suspected of being responsible for sarcopenia:
|
1 month after the of inclusion
|
|
Identify circulating mediators that could be responsible for complications of liver disease: released by the muscle and acting on the different organs
기간: 1 month after the of inclusion
|
Circulating concentration of mediators / cells suspected of being released by muscle and contributing to organ dysfunction in liver disease:
|
1 month after the of inclusion
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (예상)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .